Did You Know...
...that the first rickshaw was invented in 1869 by an American Baptist minister, the Rev. E. Jonathan Scobie, to transport his invalid wife around the streets of Yokohama?
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120107250 | ABUSE-PROOFED DOSAGE FORM An abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at l... | 05/03/2012 |
| 20120108570 | Pharmacological Treatment for Sleep Apnea The present invention relates generally to pharmacological methods for the prevention of amelioration of sleep-related breathing disorders via administration of agents or combinations of agents that possess serotonin-related pharmacological activity.... | 05/03/2012 |
| 20120071446 | DOSAGE REGIMEN OF AN S1P RECEPTOR AGONIST S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial 3 to 6 days of treatment the daily dosage is raised so that in total the R-fold (R being the accumulation factor) standard daily dosage is administered and thereaf... | 03/22/2012 |
| 20120040976 | SMALL MOLECULE IMMUNOMODULATORS FOR ALZHEIMER'S DISEASE Disclosed are methods for identifying individuals suffering from a CNS disorder (including Alzheimer's Disease, ALS, behavioral disorders, and the like) that could be treated with a CNS drug with greater therapeutic efficacy and lower side effects and the compounds usef... | 02/16/2012 |
| 20120039963 | 3-(2-Dimethlaminomethyl Cyclohexyl)Phenol Retard Formulation A pharmaceutical dosage form for controlled release of the active substance 3-(2-dimethylaminomethylcyclohexyl)-phenol, preferably (1R,2R)-3-(2-dimethylaminomethylcyclohexyl)-phenol, or a pharmaceutically acceptable salt thereof, which dosage form (i) in vivo produces a... | 02/16/2012 |
| 20120035269 | CYCLOPROPENE AMINE COMPOUNDS Methods of applying cyclopropene amine derivatives and compositions thereof to inhibit ethylene receptors in plants and plant material are disclosed. Methods include applying to the plant an effective ethylene response-inhibiting amount of at least one cyclopropene amin... | 02/09/2012 |
| 20120034304 | Prolonged Release Pharmaceutical Composition Containing 3-(3-Dimethylamino-1-Ethyl-2-Methyl-Propyl)Phenol A pharmaceutical formulation for prolonged release of the active ingredient 3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof in a matrix containing between 1 and 80 wt. % of at least one pharmaceutically acceptable hydrophil... | 02/09/2012 |
| 20120018333 | Reducing Side Effects of Tramadol The invention provides methods of reducing the side effects of tramadol. Accordingly, in one embodiment, the invention provides a method of reducing the incidence of newly-discovered side effects related to sexual function in human males taking a tramadol material. The ... | 01/26/2012 |
| 20120022071 | Treatment of Comorbid Premature Ejaculation and Erectile Dysfunction The invention provides a method of treating comorbid premature ejaculation and erectile dysfunction. In particular, the method comprises administering an effective amount of a tramadol material and an effective amount of a phosphodiesterase inhibitor. The invention also... | 01/26/2012 |
| 20120010213 | ORAL CONTROLLED RELEASE DOSAGE FORMS FOR WATER SOLUBLE DRUGS Disclosed herein is an oral controlled release pharmaceutical formulation comprising water-soluble drug or pharmaceutically acceptable salts thereof, in a hydrophilic matrix system, further comprising pH independent polymers present in an amount of 5% to 90% w/w in comb... | 01/12/2012 |
| 20110318321 | CONTROLLED RELEASE PHARMACEUTICAL OR FOOD FORMULATION AND PROCESS FOR ITS PREPARATION The present invention relates to a controlled release pharmaceutical or food formulation comprising at least one active pharmaceutical or food ingredient dispersed in a mixture of a glycogen with a polysaccharide, and the process for its preparation. The invention also ... | 12/29/2011 |
| 20110306673 | CRYSTALLINE FORMS OF (1RS,2RS,6RS)-6-DIMETHYLAMINOMETHYL-1-(3-METHOXYPHENYL)CYCLOHEXANE-1,3-DIOL HYDROCHLORIDE This invention relates to solid crystalline forms of (1RS,3RS,6RS)-6-Dimethylaminomethyl-1-(3-methoxy-phenyl)cyclohexane-1,3-diol hydrochloride (1), methods of producing 1, methods of use of 1, use of 1 as analgesics and pharmaceutical compositions comprising 1.... | 12/15/2011 |
| 20110301131 | Drug Delivery Implants and Processes for Their Preparation The invention discloses an implant suitable for delivery of at least one drug, the implant comprising a fibrillar collagen matrix having, as measured in Example 1, a viscosity of greater than 100 mPas, optionally greater than 103 mPas, further optionally greater than 10... | 12/08/2011 |
| 20110293640 | Cholinesterase Inhibitors for Treating Inflammation A method of treating a subject with a cytokine-mediated inflammatory disorder comprising administering to the subject an effective amount of a pharmaceutically acceptable cholinesterase inhibitor, provided that the inhibitor is not galantamine.... | 12/01/2011 |
| 20110294896 | Topical Treatment With Dapsone In G6PD-Deficient Patients The present invention provides a pharmaceutical carrier system comprising a dermatological composition that is a semi-solid aqueous gel, wherein dapsone is dissolved in the gel such that the dapsone has the capacity to cross the stratum corneum layer of the epidermis, a... | 12/01/2011 |
| 20110288113 | METHOD TO REDUCE OR ELMINATE THE USE BY A PATIENT OF A TOLERANCE-INDUCING PHARAMACOLOGICAL AGENT A multiple total daily dose regimen is developed in order to decrease the use by a patient of a tolerance-inducing pharmacological agent. In one example, the method reduces or phases out altogether a patient's chronic use of opioid drugs by use of a successive reduction... | 11/24/2011 |
| 20110286927 | ATF4 Inhibitors and Their Use for Neural Protection, Repair, Regeneration, and Plasticity In one aspect, the invention relates to a method for identifying a drug candidate with activity as a neuroprotective agent. The method includes determining whether a compound reduces ATF4 activity; and identifying the compound that reduces ATF4 activity as a drug candid... | 11/24/2011 |
| 20110275558 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS The present invention relates to the field of medical treatments for diseases and disorders. More specifically, the present invention relates to the use of the lanthionine synthetase component C-like (LANCL) proteins as therapeutic targets for novel classes of anti-infl... | 11/10/2011 |
| 20110275616 | Combination Analgesic Employing Opioid and Neutral Antagonist Methods of utilizing an opioid agonist in a mammalian subject in a manner that inhibits peripheral effects of the opioid agonist are described. The methods comprise administering the opioid agonist in an amount sufficient to confer analgesia the subject and co-administe... | 11/10/2011 |
| 20110269840 | TREATING RENAL CANCER USING A 4-[BIS[2-[(METHYLSULFONYL)OXY]ETHYL]AMINO]-2-METHYL-BENZALDEHYDE The present invention features methods of treating a mammalian subject having renal cancer by administration of certain dimethylsulfonate compounds, such as a 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-benzaldehyde. The present invention further features administration ... | 11/03/2011 |
| 20110263699 | 1-Phenyl-2-DimethylaminomethylCyclohexane Compounds and Therapies for Depressive Symptoms, Pain and Incontinence Metabolites of [2-(3-methoxyphenyl)-cyclohexylmethyl]dimethylamine as free bases and/or in the form of physiologically acceptable salts, corresponding medicaments, the use of [2-(3-methoxyphenyl)-cyclohexylmethyl]-dimethylamine and the metabolites thereof for producing ... | 10/27/2011 |
| 20110257134 | CO-CRYSTALS OF TRAMADOL AND NSAIDs The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs, processes for preparation of the same, their uses in pharmaceutical formulations, and for the treatment of various disorders, including pain.... | 10/20/2011 |
| 20110251286 | Crystalline salts and/or co-crystals of O-desmethyltramadol Salts and/or co-crystals of (+)-3-[2-(dimethylamino)-methyl-1-hydroxycyclohexyl]-phenol or of (−)-3-[2-(dimethylamino)methyl-1-hydroxy-cyclohexyl]phenol, present in crystalline form, with cinnamic acid, C8- to C10-alkane-monocarboxylic acids, C 10/13/2011 | |
| 20110244058 | Compositions and methods for treatment of pulmonary diseases and conditions The invention provides compositions and methods for treating pulmonary diseases and conditions. The provided compositions and methods utilize either low concentrations of selective α-2 adrenergic receptor agonists having a binding affinity of 300 fold or greater for α... | 10/06/2011 |
| 20110245335 | NEW INHIBITORS FOR TREATING DISEASES ASSOCIATED WITH AN EXCESS TRANSPORT OF HYALURONAN The present invention relates in general to a compound which is characterized by a formula selected from the following formulas A, B, C, D, E or F; or a pharmaceutically acceptable salt thereof. The present invention further relates to pharmaceutical composition compris... | 10/06/2011 |
| 20110245204 | CYCLOALKANE-CONTAINING SPHINGOSINE 1-PHOSPHATE AGONISTS The present invention provides sphingosine-1-phosphate analogs that are potent, and selective agonists at one or more S1P receptors, specifically the S1P1 receptor type. The compounds invention include compounds having a phosphate moiety as well as compounds ... | 10/06/2011 |
| 20110237563 | FAST DISSOLVING DRUG DELIVERY SYSTEMS The present invention related to the administration of bioactive agents via oral fast dispersing/dissolving drug delivery systems for treating illnesses of patient with critical buccal condition, leading to difficulties in swallowing oral medicine forms and thus difficu... | 09/29/2011 |
| 20110217249 | Compositions and Methods for the Treatment of Skin Diseases and Disorders Using Antimicrobial Peptide Sequestering Compounds The present invention provides compositions containing one or more antimicrobial peptide sequestering compounds and methods for topical application of such compositions to the skin to treat skin diseases and disorders such as rosacea in humans.... | 09/08/2011 |
| 20110218102 | DISPERSABLE POTASH GRANULE A water-dispersible particle is provided that includes organic origin potash in an amount ranging from 5% to 99.9% by weight of the total dry weight of the particle. A binder component is present in an amount from 1% to 95% by weight. The organic origin potash and the b... | 09/08/2011 |
| 20110217374 | PHARMACEUTICAL COMPOSITION SIMULTANEOUSLY HAVING RAPID-ACTING PROPERTY AND LONG-ACTING PROPERTY Disclosed is a pharmaceutical composition simultaneously having a rapid acting property and a long-acting property, comprising a sustained-release part coated with a water-insoluble polymer on the surface, comprising a first active pharmaceutical ingredient, at least on... | 09/08/2011 |
| 20110212173 | Controlled Release Treatment of Depression There is described a pharmaceutical composition for controlled release of an active compound wherein the active compound is selected from the group comprising tramadol, resveratrol, acetaminophen, xorphanol, cinfenoac, furcloprofen, bismuth subsalicylate, enofelast, tri... | 09/01/2011 |
| 20110207761 | Diversion- and/or abuse-resistant aompositions and methods for making the same A composition formulated for diversion- and/or abuse-resistance, includes at least one active pharmaceutical ingredient (API), each present in an acidic form, a first compound capable of coupling to the acidic form of the API to form a complex, where the resulting compl... | 08/25/2011 |
| 20110195116 | RATE MODULATED DELIVERY OF DRUGS FROM A COMPOSITE DELIVERY SYSTEM This invention relates to a pharmaceutical dosage form for the delivery of at least one active pharmaceutical ingredient (API) or the pharmaceutically active salts and isomers thereof, to a desired absorption location of the human or animal body, preferably the gastroin... | 08/11/2011 |
| 20110195979 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA A compound of formula (I) as well as pharmaceutically acceptable salt thereof, wherein R1 to R4 and Ar are as defined in description and in claims, can be used as a medicament.... | 08/11/2011 |
| 20110195995 | Methods of Optimizing Treatment of Estrogen-Receptor Positive Breast Cancers Estrogen-receptor positive and progesterone-receptor positive breast cancer treatment can be optimized by determining the level of expression of genes in a breast sample from a human having an estrogen-receptor positive and progesterone-receptor positive breast cancer t... | 08/11/2011 |
| 20110189269 | Extended release composition containing tramadol The present invention relates to a once daily extended release pharmaceutical preparation of Tramadol or its acceptable pharmaceutical salts. The preparation provides, effective blood concentration for a period of about 24 hours with reduce... | 08/04/2011 |
| 20110189210 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION The present invention aims at provision of a method for inhibiting remnant lipoprotein production and a remnant lipoprotein production inhibitor, which includes administering a compound having a CETP inhibitory activity to an administration subject. The remnant lipoprot... | 08/04/2011 |
| 20110160228 | DIHYDRO-ISO-CA-4 AND ANALOGUES: POTENT CYTOTOXICS, INHIBITORS OF TUBULIN POLYMERIZATION The present invention relates to compounds of formula (I) below in which: —R1 and R3 represent, independently of one another, a methoxy group optionally substituted by one or more fluorine atoms, —R2 and R4 represent, inde... | 06/30/2011 |
| 20110158983 | COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES In alternative embodiments, this invention provides compositions and methods for treating cancer or any condition caused by dysfunctional cells, side effects from treatments for cancer or any condition caused by dysfunctional cells, e.g., mucositis therapies (e.g., for ... | 06/30/2011 |
| 20110150766 | Transdermal patch with fatal overdose protection A transdermal patch having a top region containing an antagonist followed by a bottom region containing an agonist, whereby the bottommost end of the bottom region is secured to the skin of the patient for delivering a prescribed dosage of agonist to the patient over a ... | 06/23/2011 |
